Janux Therapeutics: Funding, Investors & Team (Sep 2026)
Janux Therapeutics specializes in the creation of immunotherapies that stimulate the immune system to hinder tumor growth while leaving unaffected the healthy cells of the patient. The Janux technology focuses on all three phases of the immune response against tumors.
Janux Therapeutics has raised $535M across 3 funding rounds on record, the most recent an undisclosed round of $350M announced in Dec 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Janux Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2024.
Janux Therapeutics Funding Rounds
Janux Therapeutics raised $125M in a Series B announced in Apr 2021.
2.3 years later, an undisclosed round of $60.0M was announced in Jul 2023.
1.4 years later, an undisclosed round of $350M was announced in Dec 2024.
Janux Therapeutics Founders and Leadership Team
Contact details for the Janux Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Janux Therapeutics Funding Compared to Other Biotechnology Startups
Janux Therapeutics' latest round of $350M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Janux Therapeutics in Biotechnology and La Jolla
Companies Similar to Janux Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Janux Therapeutics Funding FAQs
What does Janux Therapeutics do?
Janux Therapeutics specializes in the creation of immunotherapies that stimulate the immune system to hinder tumor growth while leaving unaffected the healthy cells of the patient. The Janux technology focuses on all three phases of the immune response against tumors.
How much funding has Janux Therapeutics raised?
Janux Therapeutics has raised $535M across 3 rounds on record. The most recent is an undisclosed round of $350M announced in Dec 2024.
When did Janux Therapeutics last raise funding?
Janux Therapeutics' most recent funding round on record is an undisclosed round of $350M, announced in Dec 2024.
Who is the CEO of Janux Therapeutics?
David Campbell is listed as CEO at Janux Therapeutics.
Where is Janux Therapeutics headquartered?
Janux Therapeutics is based in La Jolla, California, United States.
How many employees does Janux Therapeutics have?
Janux Therapeutics is in the 51-100 employee band.
How does Janux Therapeutics' funding compare to other Biotechnology startups?
Janux Therapeutics' latest round of $350M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Janux Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Janux Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.